Compare Incyte Corporation (INCY) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Nvidia Corp — how do they compare? Incyte Corporation trades at $118.03 (market cap $23.11B), while Nvidia Corp trades at $205.03 (market cap $4.92T). The key difference: Nvidia Corp is far larger — about 212.9× Incyte Corporation's market cap, and Nvidia Corp pays a 0.49% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | NVDA | |
|---|---|---|
Market Cap | $23.11B | $4.92T |
Sector | Health | Technology |
52-Week High | $118.52 | $235.75 |
52-Week Low | $67.38 | $165.17 |
Enterprise Value | $19.13B | $4.86T |
Dividend Yield | — | 0.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
NVIDIA (NVDA) trades at $205.95, up 1.55% on the day, with a neutral technical signal. The stock exhibits exceptional fundamental strength, with revenue surging to $130.50B in 2025 and net income margin reaching 62.97%. Recent quarterly earnings have consistently exceeded expectations, and analyst consensus remains strongly bullish with a $325.86 price target, though some institutional investors have recently trimmed positions.
The outlook is supported by dominant positioning in AI infrastructure, with revenue growth expected to continue. Key risks include peak AI spending concerns, intensifying competition, and high valuation multiples. The stock's performance is closely tied to the sustainability of the AI investment cycle and its ability to maintain technological leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
